Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Codiak BioSciences stock | $15.08

Learn how to easily invest in Codiak BioSciences stock.

Codiak BioSciences Inc
- $0.55 ( - 3.65%)

Codiak BioSciences Inc is a biotechnology business based in the US. Codiak BioSciences shares (CDAK) are listed on the NASDAQ and all prices are listed in US Dollars. Codiak BioSciences employs 105 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Codiak BioSciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CDAK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Codiak BioSciences stock price (NASDAQ: CDAK)

Use our graph to track the performance of CDAK stocks over time.

Codiak BioSciences shares at a glance

Information last updated 2021-10-17.
Latest market close$15.08
52-week range$7.90 - $37.85
50-day moving average $16.79
200-day moving average $18.26
Wall St. target price$36.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.79

Buy Codiak BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Codiak BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Codiak BioSciences price performance over time

Historical closes compared with the close of $15.08 from 2021-10-21

1 week (2021-10-15) 1.75%
1 month (2021-09-23) -20.00%
3 months (2021-07-23) -9.65%
6 months (2021-04-23) -17.01%
1 year (2020-10-22) 59.92%
2 years (2019-10-19) N/A
3 years (2018-10-19) N/A
5 years (2016-10-19) N/A

Codiak BioSciences financials

Revenue TTM $16.7 million
Gross profit TTM $-71,066,000
Return on assets TTM -36.79%
Return on equity TTM -442.29%
Profit margin 0%
Book value $2.33
Market capitalisation $330.9 million

TTM: trailing 12 months

Shorting Codiak BioSciences shares

There are currently 515,832 Codiak BioSciences shares held short by investors – that's known as Codiak BioSciences's "short interest". This figure is 7.2% up from 481,053 last month.

There are a few different ways that this level of interest in shorting Codiak BioSciences shares can be evaluated.

Codiak BioSciences's "short interest ratio" (SIR)

Codiak BioSciences's "short interest ratio" (SIR) is the quantity of Codiak BioSciences shares currently shorted divided by the average quantity of Codiak BioSciences shares traded daily (recently around 69801.353179973). Codiak BioSciences's SIR currently stands at 7.39. In other words for every 100,000 Codiak BioSciences shares traded daily on the market, roughly 7390 shares are currently held short.

To gain some more context, you can compare Codiak BioSciences's short interest ratio against those of similar companies.

However Codiak BioSciences's short interest can also be evaluated against the total number of Codiak BioSciences shares, or, against the total number of tradable Codiak BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codiak BioSciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Codiak BioSciences shares in existence, roughly 20 shares are currently held short) or 0.0359% of the tradable shares (for every 100,000 tradable Codiak BioSciences shares, roughly 36 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Codiak BioSciences.

Find out more about how you can short Codiak BioSciences stock.

Codiak BioSciences share dividends

We're not expecting Codiak BioSciences to pay a dividend over the next 12 months.

You may also wish to consider:

Codiak BioSciences overview

Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc. , Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

What percentage of Codiak BioSciences is owned by insiders or institutions?
Currently 0.094% of Codiak BioSciences shares are held by insiders and 82.065% by institutions.
How many people work for Codiak BioSciences?
Latest data suggests 105 work at Codiak BioSciences.
When does the fiscal year end for Codiak BioSciences?
Codiak BioSciences's fiscal year ends in December.
Where is Codiak BioSciences based?
Codiak BioSciences's address is: 35 Cambridge Park Drive, Cambridge, MA, United States, 02140
What is Codiak BioSciences's ISIN number?
Codiak BioSciences's international securities identification number is: US1920101060

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site